bluuebunny/crossref_metadata_2025_split huggingface dataset:
Use of behavioural activation to manage pain: a scoping review protocol
Authors: Walsh Sandra , Jones Martin , Gray Richard John , Gillam Marianne , Gunn Kate M , Barker Trevor , Eshetie Tesfahun , Moseley G Lorimer 
Published: June 2021

IntroductionChronic pain is a distressing condition and often poorly treated and managed. Psychological therapies are considered first-line intervention for people with chronic pain. Common psychological therapies require extensive clinician training and specialist qualifications. One approach that does not need lengthy training nor specialist qualification, but has empirical support in other health domains, is behavioural activation (BA). BA seeks to increase engagement in behaviours that are valued by the person and progress through behaviours that can increase mood and develop skills that build satisfying routines. BA can help people to manage their condition through scheduling behaviours, promoting routine and mastery over their condition. The extent to which BA has been used to support people living with chronic pain is not clear.Methods and analysisThis scoping review aims to identify published studies describing the application of BA to support people living with chronic pain. To map the evidence regarding BA and chronic pain, including the study type and the associated evidence, a scoping review was adopted. The search will be conducted in bibliographic databases, clinical trial registries and grey literature. No date limits will be applied to the search strategy. Screening of titles and abstracts, and full-text screening, will be independently undertaken by two investigators using Covidence software. Any disagreement between investigators will be resolved by a third investigator. Data from included publications will be extracted using a customised data extraction tool.Ethics and disseminationThe scoping review is an analysis of existing data and therefore ethics approval is not required. The findings of this scoping review will further our understanding of how BA has been used to support people living with chronic pain and inform future training and education programmes in this area.
Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours
Authors: Wang Shuhang , Huang Hui-Yao , Wu Dawei , Fang Hong , Ying Jianming , Bai Ying , Yu Yue , Fang Yuan , Jiang Ning , Sun Chao , Yu Anqi , Fan Qi , Xing Shujun , Ni Yufen , Zhang Wei , Wu Chenhua , Ji Xinqian , Wang Hui , Guo Yaqian , Tang Qiyu , Wang Yuan , Tang Yu , Li Ning 
Published: June 2021

IntroductionLimited clinical studies have been conducted on rare solid tumours, and there are few guidelines on the diagnosis and treatment, including experiences with targeted therapy and immunotherapy, of rare solid tumours in China, resulting in limited treatment options and poor outcomes. This study first proposes a definition of rare tumours and is designed to test the preliminary efficacy of targeted and immunotherapy drugs for the treatment of rare tumours.Methods and analysisThis is a phase II, open-label, non-randomised, multiarm, single-centre clinical trial in patients with advanced rare solid tumours who failed standard treatment; the study aims to evaluate the safety and efficacy of targeted drugs in patients with advanced rare solid tumours with corresponding actionable alterations, as well as the safety and efficacy of immune checkpoint (programmed death receptor inhibitor 1, PD-1) inhibitors in patients with advanced rare solid tumours without actionable alterations. Patients with advanced rare tumours who fail standardised treatment and carry actionable alterations (Epidermal growth factor receptor (EGFR) mutations, ALK gene fusions, ROS-1 gene fusions, C-MET gene amplifications/mutations, BRAF mutations, CDKN2A mutations, BRCA1/2 mutations, HER-2 mutations/overexpressions/amplifications or C-KIT mutations) will be enrolled in the targeted therapy arm and be given the corresponding targeted drugs. Patients without actionable alterations will be enrolled in the PD-1 inhibitor arm and be treated with sintilimab. After the patients treated with vemurafenib, niraparib and palbociclib acquire resistance, they will receive combination treatment with sintilimab or atezolizumab. With the use of Simon’s two-stage Minimax design, and the sample size was estimated to be 770. The primary endpoint of this study is the objective response rate. The secondary endpoints are progression-free survival in the targeted treatment group and single-agent immunotherapy group; the duration of response in the targeted therapy and single-agent immunotherapy groups; durable clinical benefit in the single-agent immunotherapy group; and the incidence of adverse events.Ethics and disseminationEthics approval was obtained from the Chinese Academy of Medical Sciences (ID: 20/132-2328). The results from this study will be actively disseminated through manuscript publications and conference presentations.Trial registration numbersNCT04423185; ChiCTR2000039310.
Gender difference in unmet need for assistance with activities of daily living among disabled seniors in China : a cross-sectional study
Authors: Chen Na , Li Xin , Deng Min , Wang Chang Qing , Zhou Chengchao 
Published: June 2021

ObjectivesThis study explores the gender difference in unmet need for assistance with activities of daily living among older adults with disabilities in China.DesignLogistic regression analysis was employed to examine the gender difference and identify influential factors among disabled male and female seniors.Setting23 provinces throughout China.ParticipantsA total of 1700 disabled seniors were included in the analysis.ResultsOf 1700 respondents, 619 (36.4%) were disabled male seniors. Overall, the possibility of unmet need for activity of daily living assistance among disabled female seniors was significantly lower than that among male group (OR 0.728; 95% CI 0.559 to 0.948) than males. Family care resources, economic status and loneliness were influential factors among disabled seniors regardless of genders. Furthermore, disabled female seniors from rural area (p=0.011), whose primary caregiver was willing to take care of them (p=0.022), whose community could provide daily life service (p=0.002) were more likely to have unmet need. Meanwhile, disabled female seniors whose community could provide medical service(p=0.001) were less likely to report unmet need.ConclusionsThe study showed that disabled male seniors were more likely to experience unmet need compared with female ones. Reducing unmet need for assistance with activities of daily living among disabled seniors and existing gender disparities therefore requires not only universal strategy, but also targeted policies which should be made or modified for disabled seniors of different genders.
Impact of COVID-19 pandemic social restriction measures on people with rheumatic and musculoskeletal diseases in the UK: a mixed-methods study
Authors: Smith Toby O , Belderson Pippa , Dainty Jack R , Birt Linda , Durrant Karen , Chipping Jacqueline R , Tsigarides Jordan , Yates Max , Naughton Felix , Werry Sarah , Notley Caitlin , Shepstone Lee , MacGregor Alex J 
Published: June 2021

ObjectivesTo determine the impact of COVID-19 pandemic social restriction measures on people with rheumatic and musculoskeletal diseases (RMDs) and to explore how people adapted to these measures over time.DesignMixed-methods investigation comprising a national online longitudinal survey and embedded qualitative study.SettingUK online survey and interviews with community-dwelling individuals in the East of England.ParticipantsPeople in the UK with RMDs were invited to participate in an online survey. A subsection of respondents were invited to participate in the embedded qualitative study.Primary and secondary outcome measuresThe online survey, completed fortnightly over 10 weeks from April 2020 to August 2020, investigated changes in symptoms, social isolation and loneliness, resilience and optimism. Qualitative interviews were undertaken assessing participant’s perspectives on changes in symptoms, exercising, managing instrumental tasks such a shopping, medication and treatment regimens and how they experienced changes in their social networks.Results703 people with RMDs completed the online survey. These people frequently reported a deterioration in symptoms as a result of COVID-19 pandemic social restrictions (52% reported increase vs 6% reported a decrease). This was significantly worse for those aged 18–60 years compared with older participants (p=0.017). The qualitative findings from 26 individuals with RMDs suggest that the greatest change in daily life was experienced by those in employment. Although some retired people reported reduced opportunity for exercise outside their homes, they did not face the many competing demands experienced by employed people and people with children at home.ConclusionsPeople with RMDs reported a deterioration in symptoms when COVID-19 pandemic social restriction measures were enforced. This was worse for working-aged people. Consideration of this at-risk group, specifically for the promotion of physical activity, changing home-working practices and awareness of healthcare provision is important, as social restrictions continue in the UK.
Characterising the long-term clinical outcomes of 1190 hospitalised patients with COVID-19 in New York City: a retrospective case series
Authors: Shoucri Sherif M , Purpura Lawrence , DeLaurentis Clare , Adan Matthew A , Theodore Deborah A , Irace Alexandria Lauren , Robbins-Juarez Shelief Y , Khedagi Apurva M , Letchford Daniel , Harb Amro A , Zerihun Lillian M , Lee Kate E , Gambina Karen , Lauring Max C , Chen Noah , Sperring Colin P , Mehta Sanket S , Myers Ellen L , Shih Hueyjong , Argenziano Michael G , Bruce Samuel L , Slater Cody L , Tiao Jonathan R , Natarajan Karthik , Hripcsak George , Chen Ruijun , Yin Michael T , Sobieszczyk Magdalena E , Castor Delivette , Zucker Jason E 
Published: June 2021

ObjectiveTo characterise the long-term outcomes of patients with COVID-19 admitted to a large New York City medical centre at 3 and 6 months after hospitalisation and describe their healthcare usage, symptoms, morbidity and mortality.DesignRetrospective cohort through manual chart review of the electronic medical record.SettingNewYork-Presbyterian/Columbia University Irving Medical Center, a quaternary care academic medical centre in New York City.ParticipantsThe first 1190 consecutive patients with symptoms of COVID-19 who presented to the hospital for care between 1 March and 8 April 2020 and tested positive for SARS-CoV-2 on reverse transcriptase PCR assay.Main outcome measuresType and frequency of follow-up encounters, self-reported symptoms, morbidity and mortality at 3 and 6 months after presentation, respectively; patient disposition information prior to admission, at discharge, and at 3 and 6 months after hospital presentation.ResultsOf the 1190 reviewed patients, 929 survived their initial hospitalisation and 261 died. Among survivors, 570 had follow-up encounters (488 at 3 months and 364 at 6 months). An additional 33 patients died in the follow-up period. In the first 3 months after admission, most encounters were telehealth visits (59%). Cardiopulmonary symptoms (35.7% and 28%), especially dyspnoea (22.1% and 15.9%), were the most common reported symptoms at 3-month and 6-month encounters, respectively. Additionally, a large number of patients reported generalised (26.4%) or neuropsychiatric (24.2%) symptoms 6 months after hospitalisation. Patients with severe COVID-19 were more likely to have reduced mobility, reduced independence or a new dialysis requirement in the 6 months after hospitalisation.ConclusionsPatients hospitalised with SARS-CoV-2 infection reported persistent symptoms up to 6 months after diagnosis. These results highlight the long-term morbidity of COVID-19 and its burden on patients and healthcare resources.
In situ simulation improves perceived self-efficacy of OR nurses and anaesthesiologists during COVID-19 pandemic
Authors: Lois Fernande , Hallet Claude , Samalea Suarez Nicolas , Ghuysen Alexandre , Brichant Jean François 
Published: June 2021

IntroductionSelf-efficacy is defined as people’s internal beliefs about their ability to have an impact on events that affect their lives. As part of the COVID-19 pandemic, we carried out in situ simulation for anaesthesiologists and operating room (OR) nurses. Simulation was focused on the recommendations on the use of specific personal protective equipment (PPE) as well as on airway management and intubation. We hypothesised that in situ procedural simulation should increase their perceived self-efficacy.MethodsBetween 16 March and 20 March 2020, 208 healthcare workers took part in in situ procedural simulation. A questionnaire was sent to participants on 21 April 2020. Six self-efficacy items related to PPE and airway manoeuvres were assessed before and after training on a Numeric Rating Scale from 0 to 10.ResultsSixty-seven participants (32%) replied to the questionnaire. The before–after comparison of the six items revealed an increase in perceived self-efficacy for each of them. A before training difference was observed between nurses, board-certified anaesthetists and trainees in anaesthesia in perceived self-efficacy for putting on (6 (3–8) vs 4.5 (2.25–6) vs 2 (0–6), p=0.007) and remove PPE (8 (5–8) vs 4.5 (3.25–6) vs 4 (1–6), p=0.009). No difference in perceived self-efficacy after training was observed between nurses, board-certified anaesthetists and trainees in anaesthesia.ConclusionsIn situ simulation improves the perceived self-efficacy of OR nurses and anaesthesiologists on specific skills related to the care of patients with COVID-19.
Realization of rapid synthesis of H-ZSM-5 zeolite by seed-assisted method for aromatization reactions of methanol or methane
Authors: Tian HaiFeng , Yang Xing , Tian HaiZhou , Zha Fei , Guo XiaoJun , Tang XiaoHua 
Published: June 2021

H-ZSM-5 zeolites are successfully synthesized within 1 h with an organic template free system by the seed-assisted method. The synthetic method not only reduces the production cost of H-ZSM-5 zeolite, but also decreases the environmental pollution produced compared with that of the conventional synthesis process. Characterization by SEM, XRD, N2 adsorption–desorption, NH3-TPD, and Py-IR confirms that the H-ZSM-5 product has a high crystallinity and reveals that the rapid synthesis process is in accordance with the seed surface crystallization mechanism. To improve the aromatic selectivity on the H-ZSM-5 zeolite, different concentrations of Mo and Zn catalysts were prepared by incipient wetness impregnation and the ion-exchange method. Mo-Zn/H-ZSM-5-SAS-1 h have similar catalytic lifetimes and higher selectivity of paraxylene in aromatic products compared with Mo-Zn/H-ZSM-5-seed in the reaction of methanol to aromatic. However, the catalytic lifetime of 6%Mo/H-ZSM-5-SAS-1 h is shorter than that of the 6%Mo/H-ZSM-5-seed catalyst in methane to benzene reaction under the same reaction conditions.
xPPN: an implementation of the parametrized post-Newtonian formalism using xAct for Mathematica
Authors: Hohmann Manuel 
Published: June 2021

AbstractWe present a package for the computer algebra system Mathematica, which implements the parametrized post-Newtonian (PPN) formalism. This package, named xPPN, is built upon the widely used tensor algebra package suite xAct, and in particular the package xTensor therein. The main feature of xPPN is to provide functions to perform a proper $$3+1$$

3
+
1

decomposition of tensors, as well as a perturbative expansion in so-called velocity orders, which are central tasks in the PPN formalism. Further, xPPN implements various rules for quantities appearing in the PPN formalism, which aid in perturbatively solving the field equations of any metric theory of gravity. Besides Riemannian geometry, also teleparallel and symmetric teleparallel geometry are implemented.
Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival
Authors: Gillani Riaz , Seong Bo Kyung A. , Crowdis Jett , Conway Jake R. , Dharia Neekesh V. , Alimohamed Saif , Haas Brian J. , Han Kyuho , Park Jihye , Dietlein Felix , He Meng Xiao , Imamovic Alma , Ma Clement , Bassik Michael C. , Boehm Jesse S. , Vazquez Francisca , Gusev Alexander , Liu David , Janeway Katherine A. , McFarland James M. , Stegmaier Kimberly , Van Allen Eliezer M. 
Published: June 2021

AbstractGene fusions frequently result from rearrangements in cancer genomes. In many instances, gene fusions play an important role in oncogenesis; in other instances, they are thought to be passenger events. Although regulatory element rearrangements and copy number alterations resulting from these structural variants are known to lead to transcriptional dysregulation across cancers, the extent to which these events result in functional dependencies with an impact on cancer cell survival is variable. Here we used CRISPR-Cas9 dependency screens to evaluate the fitness impact of 3,277 fusions across 645 cell lines from the Cancer Dependency Map. We found that 35% of cell lines harbored either a fusion partner dependency or a collateral dependency on a gene within the same topologically associating domain as a fusion partner. Fusion-associated dependencies revealed numerous novel oncogenic drivers and clinically translatable alterations. Broadly, fusions can result in partner and collateral dependencies that have biological and clinical relevance across cancer types.Significance:This study provides insights into how fusions contribute to fitness in different cancer contexts beyond partner-gene activation events, identifying partner and collateral dependencies that may have direct implications for clinical care.
RAD51AP1 Loss Attenuates Colorectal Cancer Stem Cell Renewal and Sensitizes to Chemotherapy
Authors: Bridges Allison E. , Ramachandran Sabarish , Tamizhmani Kavin , Parwal Utkarsh , Lester Adrienne , Rajpurohit Pragya , Morera Daley S. , Hasanali Sarrah L. , Arjunan Pachiappan , Jedeja Ravirajsinh N. , Patel Nikhil , Martin Pamela M. , Korkaya Hasan , Singh Nagendra , Manicassamy Santhakumar , Prasad Puttur D. , Lokeshwar Vinata B. , Lokeshwar Bal L. , Ganapathy Vadivel , Thangaraju Muthusamy 
Published: June 2021

AbstractDNA damage, induced by either chemical carcinogens or environmental pollutants, plays an important role in the initiation of colorectal cancer. DNA repair processes, however, are involved in both protecting against cancer formation, and also contributing to cancer development, by ensuring genomic integrity and promoting the efficient DNA repair in tumor cells, respectively. Although DNA repair pathways have been well exploited in the treatment of breast and ovarian cancers, the role of DNA repair processes and their therapeutic efficacy in colorectal cancer is yet to be appreciably explored. To understand the role of DNA repair, especially homologous recombination (HR), in chemical carcinogen-induced colorectal cancer growth, we unraveled the role of RAD51AP1 (RAD51-associated protein 1), a protein involved in HR, in genotoxic carcinogen (azoxymethane, AOM)–induced colorectal cancer. Although AOM treatment alone significantly increased RAD51AP1 expression, the combination of AOM and dextran sulfate sodium (DSS) treatment dramatically increased by several folds. RAD51AP1 expression is found in mouse colonic crypt and proliferating cells. RAD51AP1 expression is significantly increased in majority of human colorectal cancer tissues, including BRAF/KRAS mutant colorectal cancer, and associated with reduced treatment response and poor prognosis. Rad51ap1-deficient mice were protected against AOM/DSS-induced colorectal cancer. These observations were recapitulated in a genetically engineered mouse model of colorectal cancer (ApcMin/+). Furthermore, chemotherapy-resistant colorectal cancer is associated with increased RAD51AP1 expression. This phenomenon is associated with reduced cell proliferation and colorectal cancer stem cell (CRCSC) self-renewal. Overall, our studies provide evidence that RAD51AP1 could be a novel diagnostic marker for colorectal cancer and a potential therapeutic target for colorectal cancer prevention and treatment.Implications:This study provides first in vivo evidence that RAD51AP1 plays a critical role in colorectal cancer growth and drug resistance by regulating CRCSC self-renewal.
Correlation of Intravascular Ultrasound and Instantaneous Wave-Free Ratio in Patients With Intermediate Left Main Coronary Artery Disease
Authors: El Hajj Stephanie C. , Toya Takumi , Warisawa Takayuki , Nan John , Lewis Bradley R. , Cook Christopher M. , Rajkumar Christopher , Howard James P. , Seligman Henry , Ahmad Yousif , Doi Shunichi , Nakajima Akihiro , Nakayama Masafumi , Goto Sonoka , Vera-Urquiza Rafael , Sato Takao , Kikuta Yuetsu , Kawase Yoshiaki , Nishina Hidetaka , Nakamura Sunao , Matsuo Hitoshi , Escaned Javier , Akashi Yoshihiro J. , Davies Justin E. , Lerman Amir 
Published: June 2021

Background:
There is great degree of interobserver variability in the visual angiographic assessment of left main coronary disease (LMCD). Fractional flow reserve and intravascular ultrasound are often used in this setting. The use of instantaneous wave-free ratio (iFR) for evaluation of LMCD has not been well studied. The aim of this study is to evaluate the use of iFR in the assessment of angiographically intermediate LMCD.

Methods:

This is an international multicenter retrospective observational study of patients who underwent both iFR and intravascular ultrasound evaluation for angiographically intermediate LMCD. An independent core laboratory performed blinded off-line analysis of all intravascular ultrasound data. A minimum lumen area of 6 mm
2
was used as the cutoff for significant disease.

Results:

One hundred twenty-five patients (mean age, 68.4±9.5 years, 84.8% male) were included in this analysis. Receiver operating curve analysis showed that an iFR of ≤0.89 identified minimum lumen area <6 mm
2
with an area under the curve of 0.77 (77% sensitivity, 66% specificity;
P
<0.0001). Among the 69 patients without ostial left anterior descending artery or left circumflex artery disease, receiver operating curve analysis showed that an iFR of ≤0.89 identified minimum lumen area <6 mm
2
with an area under the curve of 0.84 (70% sensitivity, 84% specificity;
P
<0.0001). The correlation was not significantly different when the body surface area was considered.

Conclusions:

In this study, in patients with intermediate LMCD, iFR of ≤0.89 correlates with intravascular ultrasound minimum lumen area <6 mm
2
regardless of body surface area. The current study supports the use of iFR for the evaluation of intermediate LMCD.